The ArgumentIn Germany during the 1870s and 1880s a number of important scientific innovations in chemistry and biology emerged that were linked to advances in the new technology of synthetic dyestuffs. In particular, the rapid development of classical organic chemistry was a consequence of programs in which chemists devised new theories and experimental strategies that were applicable to the processes and products of the burgeoning dye factories. Thereafter, the novel products became the means to examine and measure biological systems. This (...) took place as a result of two trends. The first was a move toward diversification in the dye industry – made possible by the extensive range of products – which in turn was stimulated by economic and political conditions. The second was the increasing availability of techniques, substances, and processes used in industry. This made possible a concrete program of introducing the qualitative and quantitative methods of chemistry into the domain of laboratory experimentation on biological materials, thereby realizing the abstract desire to transform cell biology into an exact science.Moreover, the conceptualization of biological systems that emerged from this endeavor leaned heavily on a theory of dye chemistry that indicated which particular arrangements of atoms performed specific functions. This biological modeling used the imagery of chemical structural formulae to transform chemical nuclei and their side chains into adequate representations of protoplasmic structure. (shrink)

Whereas Pasteur patented the biotechnological processes that he invented between 1857 and 1873 in the agro-food domain, he did not file any patents on the artificial vaccine preparation processes that he subsequently developed. This absence of patents can probably be explained by the 1844 patent law in France that established the non-patentable status of pharmaceutical preparations and remedies, including those for use in veterinary medicine. Despite the absence of patents, the commercial exploitation of the anthrax vaccine in the 1880s and (...) 1890s led to a technical and commercial monopoly by Pasteur’s laboratory as well as the founding of a commercial company to diffuse the vaccine abroad. Pasteur repeatedly refused to transfer his know-how and anthrax vaccine production methods to foreign laboratories, on the grounds that he wished to control the quality of the vaccines produced. Indeed, it was relatively difficult to transfer a method that was not yet perfectly stabilized in the early 1880s. Pasteur also wanted to maintain the monopoly of his commercial company and to increase the profits from vaccine sales so that the Institut Pasteur could be financially independent. The ‘Pasteur anthrax vaccine’ operating licences are described and analysed in detail in this article. (shrink)